Press Releases

Date Headline
6/26/2023
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
 Summary
VANCOUVER, British Columbia , June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000 ® , and the Russell Microcap® Indexes  Continue Reading
6/2/2023
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
 Summary
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival  Continue Reading
6/1/2023
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies Global  Continue Reading
5/18/2023
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
 Summary
VANCOUVER, British Columbia , May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the departure of Neil Klompas , President and Chief Operating Officer. Mr.  Continue Reading
5/8/2023
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
 Summary
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Association for Cancer  Continue Reading
5/1/2023
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Bank of America  Continue Reading
4/18/2023
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
 Summary
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX)   models with favorable pharmacokinetic and safety profiles ● ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of on-target off-tumor toxicity, peripheral T cell  Continue Reading
4/17/2023
Zymeworks To Host First Quarter 2023 Results Conference Call
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 17, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8,  Continue Reading
4/10/2023
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 10, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023 . Mr.  Continue Reading
4/3/2023
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Apr. 3, 2023-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2023 Bloom Burton &  Continue Reading
Displaying 11 - 20 of 27